Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
暂无分享,去创建一个
John Seibyl | Yasuomi Ouchi | Ana M. Catafau | Kenji Ishii | Osama Sabri | Katrin Roth | Bernardino Ghetti | Shigeo Murayama | Norman Koglin | Anja Hoffmann | Cornelia Reininger | Christopher C. Rowe | Henryk Barthel | Marwan N. Sabbagh | Walter J. Schulz-Schaeffer | Masaki Takao | Thomas G. Beach | James B. Leverenz | James W. Ironside | C. Rowe | M. Sabbagh | J. Seibyl | B. Ghetti | K. Ishii | T. Beach | W. Schulz-Schaeffer | O. Sabri | H. Barthel | J. Ironside | S. Murayama | J. Leverenz | A. Catafau | Y. Ouchi | M. Takao | N. Koglin | H. Akatsu | C. Reininger | Hiroyasu Akatsu | Anja Hoffmann | K. Senda | A. Stephens | A. Mueller | Katrin Roth | Kohei Senda | Andrew W. Stephens | Andre Mueller
[1] Masanori Ichise,et al. PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.
[2] W. Kukull,et al. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.
[3] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[4] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[5] Christer Halldin,et al. Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand , 2012, The Journal of Nuclear Medicine.
[6] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[7] L. Thurfjell,et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.
[8] A. Scott,et al. A simple method for the analysis of clustered binary data. , 1992, Biometrics.
[9] C. Rowe,et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[10] M. Mintun,et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. , 2011, Archives of neurology.
[11] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[12] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[13] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[14] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[15] Clifford R Jack,et al. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. , 2012, Radiology.
[16] P. Thompson,et al. PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.
[17] A. Hirano,et al. A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES , 1986, Neuropathology and applied neurobiology.
[18] P. Mcgeer,et al. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy , 2013, Acta Neuropathologica.
[19] S. Lehéricy,et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl‐11C]‐2‐(4′‐methylaminophenyl)‐ 6‐hydroxybenzothiazole , 2011, Annals of neurology.
[20] M. Blankenburg,et al. Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.
[21] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[22] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[23] C. Rowe,et al. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. , 2012, Nuclear medicine and biology.
[24] H. Gertz,et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[25] James Robert Brašić,et al. An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients , 2013, Molecular Imaging and Biology.
[26] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[27] P. Dupont,et al. Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease☆ , 2013, NeuroImage: Clinical.
[28] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[29] B. Everitt,et al. Statistical methods for rates and proportions , 1973 .
[30] H. Braak,et al. Parenchymal and vascular Aβ-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.
[31] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.